Blimp-1的调控机制及其在血液系统恶性肿瘤中的研究进展  

Regulatory Mechanism of Blimp-1 and Its Research Progress in Hematologic Malignancies

作　　者：凌燕 高烨飞 金晶[2] 封蔚莹[2] 罗洪强[2] LING Yan;GAO Yefei;JIN Jing;FENG Weiying;LUO Hongqiang(Medical College of Shaoxing University,Shaoxing 312000,China;Department of Hematology,Shaoxing People's Hospital,Shaoxing 312000,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000 [2]绍兴市人民医院血液科,浙江绍兴312000

出　　处：《医学综述》2025年第7期798-802,共5页Medical Recapitulate

基　　金：绍兴市卫生健康委公益性技术应用研究项目(2020A13016)。

摘　　要：B淋巴细胞诱导的成熟蛋白-1(Blimp-1)是一种由PRDM1基因编码的转录调节因子,可通过其锌指N端富含脯氨酸的区域将染色质修饰因子募集到靶位点,抑制染色质修饰并调控靶基因转录,进而调控细胞增殖、分化及细胞周期进程,促进免疫细胞稳态的维持。Blimp-1与淋巴瘤、多发性骨髓瘤、急性髓系白血病等血液系统恶性肿瘤均密切相关,深入研究其在血液系统恶性肿瘤中的作用机制,可以为临床血液系统恶性肿瘤的诊治提供新的理论依据和治疗靶点。B lymphocyte-induced maturation protein-1(Blimp-1),encoded by the PRDM1 gene,functions as a transcriptional regulator that recruits chromatin-modifying factors to its target loci via its N-terminal zinc finger and proline-rich domain.This recruitment facilitates repressive chromatin modifications,thereby modulating the transcription of target genes.Consequently,Blimp-1 plays a critical role in regulating cellular proliferation,differentiation,and cell cycle progression,contributing to the maintenance of immune cell homeostasis.There is a significant association between Blimp-1 and hematological malignancies,including lymphoma,multiple myeloma,and acute myeloid leukemia.In-depth studies of the regulatory mechanisms of Blimp-1 in hematologic malignancies,can provide new theoretical references and potential therapeutic targets for the clinical management of hematologic malignancies.

关 键 词：血液系统恶性肿瘤 B淋巴细胞诱导的成熟蛋白-1 PRDM1基因 调控机制 

分 类 号：R733[医药卫生—肿瘤]